Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1E | P28566 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 3/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23326180 | 0.77 | HTR2A (0.54) | HTR2APDE4BHTR2CHTR2BHTR1A | |
| SCHEMBL29775421 | 0.77 | HTR2A (0.54) | HTR2APDE4BHTR2CHTR2BHTR1A | |
| SCHEMBL23326115 | 0.77 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL23214857 | 0.77 | PDE4B (0.50) | HTR2APDE4BSCN9A | |
| SCHEMBL29886238 | 0.77 | PDE4B (0.50) | HTR2APDE4BSCN9A | |
| SCHEMBL17304223 | 0.77 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DSCN9A | |
| SCHEMBL28782624 | 0.76 | PDE4B (0.48) | HTR2APDE4BSCN9A | |
| SCHEMBL25344756 | 0.76 | PROKR1 (0.54) | PDE4BSCN9A | |
| SCHEMBL28782629 | 0.76 | PDE4B (0.54) | PDE4BSCN9A | |
| SCHEMBL23348062 | 0.76 | HTR2A (0.50) | HTR2APDE4BSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761083-B | 5-HT for treating depression 2A Agonists | 罗福拉公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-3962601-B1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2023-05-31 | — | — | EP | disclosed |
| EP-3962601-B1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2023-05-31 | — | — | EP | disclosed |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-05-09 | — | — | US | disclosed |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-05-09 | — | — | US | disclosed |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-05-09 | — | — | US | disclosed |
| US-11633390-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-04-25 | — | — | US | disclosed |
| US-11633390-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-04-25 | — | — | US | disclosed |
| CN-114761083-A | 5-HT for the treatment of depression2AAgonists | 罗福拉公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220062257-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2022-03-03 | — | — | US | disclosed |
| US-20220062257-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2022-03-03 | — | — | US | disclosed |
| US-11246860-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2022-02-15 | — | — | US | disclosed |
| US-11246860-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2022-02-15 | — | — | US | disclosed |
| US-20210330658-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2021-10-28 | — | — | US | disclosed |
| US-20210330658-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2021-10-28 | — | — | US | disclosed |
| US-20210137908-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2021-05-13 | — | — | US | disclosed |
| US-20210137908-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330658-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | HTR2A 1/4885PDE4B 461/4885HTR2C 2/4885 |
| US-20220062257-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | HTR2A 1/4885PDE4B 461/4885HTR2C 2/4885 |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | HTR2A 1/4885PDE4B 461/4885HTR2C 2/4885 |
| US-20210137908-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | HTR2A 1/4885PDE4B 461/4885HTR2C 2/4885 |
| US-11633390-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | HTR2A 1/4885PDE4B 461/4885HTR2C 2/4885 |
| US-11246860-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | HTR2A 1/4885PDE4B 461/4885HTR2C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.